Business Wire

SAMSUNG-ELECTRONICS

12.1.2021 16:07:33 CET | Business Wire | Press release

Share
Samsung Sets New Standard for Flagship Mobile Processors with Exynos 2100

Samsung Electronics Co., Ltd., a world leader in advanced semiconductor technology, today announced the Exynos 2100 through its first virtual event, Exynos On 2021 (www.youtube.com/samsung ). The new mobile processor is the company’s first premium 5G-integrated mobile processor built on the most advanced 5-nanometer (nm) extreme ultra-violet (EUV) process node.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210112005748/en/

“Our Exynos team has been committed to creating premium mobile computing experiences by bringing innovations to processors that are at the heart of today’s smart devices,” said Inyup Kang, president of System LSI Business at Samsung Electronics. “Today we are delighted to introduce the Exynos 2100, our most advanced mobile processor yet. Armed with powerful processing technologies and an advanced 5G modem on a power-efficient 5nm process node, Exynos 2100 will set a new standard for tomorrow’s flagship mobile devices.”

“At Samsung Electronics, we are dedicated to providing innovative technologies and services with our flagship devices to deliver the ultimate mobile experience to our customers,” said Kyeongjun Kim, Executive Vice President and head of Mobile R&D Office at Mobile Communications Business, Samsung Electronics. “With powerful processing, fast 5G connectivity, and intelligent AI-acceleration, the Exynos 2100 offers the utmost performance that meets the stringent quality standards and requirements for our next generation smartphone.”

“The evolution of technologies such as 5G, advanced graphics and machine learning have been critical in enabling new mobile experiences,” said Paul Williamson, vice president and general manager, Client Line of Business at Arm. “Arm and Samsung have collaborated closely to incorporate Arm’s powerful next-generation compute and graphics platform, at the heart of the Samsung Exynos 2100. As a result of our partnership, we are able to maximize performance and make these experiences a reality in next-generation mobile devices while delivering exceptional battery life.”

The chip’s computation and graphic processing performance have been improved and refined to surpass the power user’s performance expectations. As Samsung’s first 5G-integrated flagship mobile processor, the Exynos 2100 is built on an advanced 5nm EUV process technology that allows up to 20-percent lower power consumption or 10-percent higher overall performance than the 7nm predecessor. For further enhancement, the chip offers improved cache memory utilization and a stronger scheduler. The octa-core CPU comes in an improved tri-cluster structure made up of a single powerful Arm® Cortex® -X1 core that runs at up to 2.9GHz, three high-performing Cortex-A78 cores and four power-efficient Cortex-A55 cores delivering more than 30-percent enhancement in multi-core performance than the predecessor.

The Arm Mali -G78, which supports the latest APIs such as Vulkan and OpenCL, improves graphic performance by more than 40-percent for visually stunning and seamless graphics, enabling the most immersive on-screen mobile experiences yet, including gaming and AR/VR or MR(Mixed Reality). The Exynos 2100 also integrates advanced multi-IP governor (AMIGO) technology, which overlooks and optimizes power usages of CPU, GPU, and other processes, allowing longer use time even with intense on-screen activities. With such comprehensive efforts to increase energy efficiency of its products across software and hardware technologies, Samsung also continues its strive to help minimize the carbon footprint of tomorrow’s mobile devices.

AI capabilities will also enjoy a significant boost with the Exynos 2100. The newly-designed tri-core NPU has architectural enhancements such as minimizing unnecessary operations for high effective utilization and support for feature-map and weight compression. Exynos 2100 can perform up to 26-trillion-operations-per-second (TOPS) with more than twice the power efficiency than the previous generation. With on-device AI processing and support for advanced neural networks, users will be able to enjoy more interactive and smart features as well as enhanced computer vision performance in applications such as imaging.

The Exynos 2100’s advanced image signal processor (ISP) supports camera resolutions of up to 200-megapixels (Mp). It can connect up to six individual sensors and is able to process four concurrently for richer multi-camera experiences. With a multi-camera and frame processor (MCFP), the ISP can combine feeds from multiple cameras to improve zoom performance, enhance image quality for ultra-wide shots and more. With AI acceleration, the ISP offers a content-aware feature that quickly and seamlessly recognizes scenes, faces and objects and optimally adjusts the camera settings to capture the image with fuller detail.

The Exynos 2100’s integrated 5G modem supports 5G’s sub-6GHz and mmWave spectrums from 2G GSM/CDMA, 3G WCDMA and 4G LTE, for strong network coverage and reliability. The modem delivers a maximum downlink speed of up to 5.1-gigabits per second (Gbps) in sub-6-gigahertz (GHz) and 7.35Gbps in mmWave, or up to 3.0Gbps in 4G networks with 1024 Quadrature Amplitude Modulation (QAM) support.

The Exynos 2100 is currently in mass production.

For more information about Samsung’s Exynos products, please visit http://www.samsung.com/exynos .

Process

5nm

AI

26 TOPS

Multi-core

Octa-core

CPU (Main)

Arm Cortex-X1 (2.9GHz)

CPU (Sub)

Arm Cortex-A78 and Cortex-A55

GPU

Arm Mali-G78

Connectivity

5G (sub-6GHz/mmWave), 4G LTE (1024 QAM), 3G WCDMA, 2G GSM/CDMA

Memory

LPDDR5 (51.2GB/s)

Storage

UFS 3.1, UFS 2.1

Camera (Rear)

200MP

Video (Encoding)

4K UHD 120fps

Video (Decoding)

8K 60fps

# # #

* Editor's Note: Actual performance may vary depending on device and user environment.

About Samsung Electronics Co., Ltd.

Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, digital appliances, network systems, and memory, system LSI, foundry and LED solutions. For the latest news, please visit the Samsung Newsroom at http://news.samsung.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 04:00:00 CEST | Press release

Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and

Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 01:51:00 CEST | Press release

Organon stockholders to receive US$ 14.00 per share in cashThe deal values Organon at EV of US$ 11.75 billionCombined Business leverages complementary portfolios and global scale for sustained long‑term value creation Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equit

Andersen Global udvider sin tilstedeværelse i Afrika med lanceringen af medlemsfirma i Cameroun26.4.2026 20:56:00 CEST | Pressemeddelelse

Andersen Global træder ind på det camerounske marked, idet Phoenix Advisory bliver medlemsfirma og overgår til Andersen-brandet. Andersen in Cameroun er et specialiseret rådgivningsfirma, der leverer strategiske, erhvervsmæssige, finansielle og operationelle rådgivningsydelser til organisationer i forskellige vækstfaser. Firmaet er grundlagt af fagfolk med erfaring fra store internationale organisationer og kombinerer et stærkt lokalt og centralafrikansk funderet kendskab til forretningsmæssige, juridiske og skattemæssige regler med en skræddersyet tilgang, der har til formål at skabe konkrete og målbare resultater for klienterne. "Overgangen til Andersen-brandet afspejler vores engagement i at vokse sammen med vores kunder og imødekomme stadig mere komplekse behov," udtalte administrerende partner Albert Désiré Zang. "Vi tror på, at langsigtet succes skabes gennem tillid, kvalitet og vedvarende support. At blive et medlemsfirma styrker vores evne til at levere gennemtænkte, bæredygtig

PMCOrganometallix Announces Price Increase on All Products24.4.2026 22:55:00 CEST | Press release

Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli

Frankfurt Higher Regional Court upholds BESREMi® arbitral award in favor of AOP Health24.4.2026 18:52:00 CEST | Press release

Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye